Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Rivaldo. Thanks for this and your other posts on this board. Very helpful. One more top up on CAPD for me, maybe tomorrow, and I'm fully loaded. Then hold for the foreseeable. SP growth potential looks very good and they even pay a dividend.
- Record pre-R&D operating profit ahead of market expectations reflecting continued sales growth
- Successful ex-vivo VLP Peanut biomarker study showing 24-fold reduction in allergenicity and beneficial efficacy profile paving the way for first-in-human trial in 2022
- Strong cash balance of £40.3m providing sufficient funds with a small amount of debt under current assumptions to support Grass MATA MPL pivotal Phase III field studies and Phase I VLP Peanut PROTECT trial
Financial highlights
· 8% revenue growth in actual terms and 6% at constant rate* to £84.3m (2020: £78.2m)
· 19% increase in pre-R&D operating profit to £16.9m (2020: £14.2m) as a result of sales growth and lower overhead cost growth
· Strong cash balance of £40.3m at 30 June 2021 (2020: £37.0m)
· Net profit of £2.9m for the year (2020: Net profit of £7.1m including cash settlement of £3.2m)
Operating highlights (including post period)
· Successful ex-vivo VLP Peanut biomarker study ahead of Phase I trial (named PROTECT) anticipated in Q1 2022
· Robust growth across all key products and countries in a challenging year
· Successful launch of ImmunoBON in Germany and Austria
· Grass MATA MPL exploratory field trial to read out in autumn 2021
· Registration of Venomil in Austria
Manuel Llobet, CEO of Allergy Therapeutics, stated: "Allergy Therapeutics has performed well in 2021, driving our European commercial business and progressing our clinical programmes amid challenging conditions. Our commercial and pipeline products demonstrate our commitment to allergy and immunology solutions to help people worldwide.
"Engaging with our stakeholders is key to our success as a business. They trust us to deliver safe and effective products on time, to stand by our values and to operate our business with high standards of quality and integrity. Our three core values - Vision, Commitment and Menschlichkeit (Humanity), shape the way in which we work and are at the heart of every decision we make. I would like to thank our team and all our partners for their contribution to another successful year."
Analyst briefing and webcast today
Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will host a virtual presentation for analysts to provide an update on the Group, followed by a Q&A session, at 09.30am BST.
The live webcast can be accessed here.
Launch LYCRA® freshFX® Brand with HeiQ Technology for the China Market
https://www.businesswire.com/news/home/20210921006126/en/HeiQ-and-The-LYCRA-Company-Launch-LYCRA%C2%AE-freshFX%C2%AE-Brand-with-HeiQ-Technology-for-the-China-Market
Chris Mills' Harwood Capital increasing their holding to 18.55%
Share price forecast: "Shares in DX (Group) are currently priced at 31.5p. At that level they are trading at 65.89% discount to the analyst consensus target price of 92.35p"
Jamie Constable discusses logistics companies including DX from about 5:40mins. Good management now in place, share price is cheap, plenty of upside.
https://youtu.be/jA4Zdcrm18M
Interview with Jamie Constable - from 4:40mins
https://youtu.be/jA4Zdcrm18M
Always good to see directors getting more "skin in the game"
Agreed. Definitely heading in the right direction and a prime candidate for take over. (worth listening again to Chris Mills interview of 28th June with Paul Hill on Vox Markets from 33:40mins for his take on things at CIR)
VRCI has been shortlisted in the Best Technology Award category
https://www.aim-awards.co.uk/nominations-overview/
EKF has been shortlisted in a few categories in the AIM awards.
https://www.aim-awards.co.uk/nominations-overview/
Attended today's results presentation on Walbrook. Really impressed. Future looks great here. I assume they will issue a recording of the event for those who couldn't attend. I'll post a link when they do. Very much worth a watch.
Has opened a new position here and AMYT has jumped to the top of the most followed companies on V o x Markets.
May, therefore , generate some new buying (as it should. I rate Paul highly after previous tips)
He reckons on a SP of £2:40 to £5 over the coming years
6:30 minutes into the following: https://youtu.be/fb16Yg6XiD8
Will be tuning into the Capital Markets day tomorrow at 3:00pm https://lifesci.rampard.com/WebcastingAppv5/Events/eventsDispatcher.jsp?Y2lk=MTM1Mw==
Adam Davidson on tonight at 6:00pm. Click link to register
https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-080921